Gilead Sciences (GILD) Tops Q2 EPS by 41c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Gilead Sciences (GILD) PT Raised to $81 at Deutsche Bank; Light at the End of the Tunnel
July 27, 2017 8:30 AM EDTDeutsche Bank analyst Andrew Peters raised his price target on Gilead Sciences (NASDAQ: GILD) to $81.00 (from $79.00) while maintaining a Buy rating.
Peters commented, "We are reiterating our Buy rating on GILD and establishing a new $81 price target following a strong beat-and-raise quarter which saw... More
